Taipei, Taiwan, 1 Feburary 2023 -- Lotus Pharmaceutical (“Lotus” or “the Company,” Taiwan TWSE ticker: 1795), a multinational pharmaceutical company, announced today that together with Adalvo, we have partnered with Eurofarma, to launch Lenalidomide in the Brazilian market under the brand name Nuvyor.
Nuvyor is the first similar molecule in the Brazilian market and is used in the treatment of multiple myeloma - a disease that affects plasma cells, bone marrow cells responsible for the production of antibodies that fight infections. The drug, has been developed and manufactured by Lotus, arrived at hospitals and clinics in October last year.
This strategic partnership with Adalvo and Eurofarma has enhanced accessibility of vital medications to patients in Brazil with a safe and cost-effective alternative for multiple myeloma and expands Lotus’s reach to this most important market in South America.
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners. The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About The Eurofarma Group
For 50 years, the Eurofarma Group has been operating in the health sector, producing and marketing products and services to improve people's quality of life. With diversified operations, it operates in all major segments, such as Medical Prescription, Prescription-Free, Generic, Hospital and Oncology. In Brazil alone, it offers more than 430 products, serves all medical specialties, covering more than 200 therapeutic classes, representing 80% of the total market.
The Eurofarma Group is present in more than 20 countries, with 10 production plants in Latin America. In 2021, it generated net sales of R$ 7 billion and employs more than 8,800 employees.